GLIMEPIRIDE 1mg. IP + METFORMIN 500mg. IP + VOGLIBOSE 0.2mg. IP

A triple combination of anti-diabetic drugs that are used to treat type 2 diabetes mellitus in adults. Controls high blood glucose levels, reduces pill burden, and dosing frequency, and improves adherence. (Ashok K. Das, 2022) Effectively manages the levels of postprandial blood glucose as well as fasting plasma glucose in achieving adequate glycemic control. (Ganapathi Bantwal, 2021) Potentially improves glycemic control and delays microvascular and cardiovascular complications. (Ashok K. Das, 2022) An efficacious agent that reduces the risk of weight gain in patients with Type 2 diabetes mellitus. (Ganapathi Bantwal, 2021) Alleviates the risk of developing co-morbidities associated with weight gain (obesity and dyslipidemia). (Ganapathi Bantwal, 2021) A promising treatment option for the clinical management of uncontrolled glycemia and improves compliance with the treatment. (Ganapathi Bantwal, 2021) Delays glucose absorption from the intestines and increases the body's response to insulin. (Ashok K. Das, 2022) Shows a very significant benefit in controlling the glucose triad levels [HbA1c, FPG, and PPHG] as compared to dual therapy [metformin 500mg + glimepiride 1mg]. (Rajesh Kumar Manchi, 2021)